Our approach to venture investments
We strive to invest in companies that develop innovative drugs, medical devices and diagnostics.
We focus on generating strong financial returns from our portfolio of venture companies. We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective.
With colleagues on the ground in Copenhagen, London, Singapore, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge.
We primarily invest in biotechnology and medical technology. Within biotech we primarily invest in companies with clinical stage compounds. In medtech, we invest in commercial stage companies.
We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences.
Novo Ventures executed 79 investments in 2020 and among its exits were 9 IPOs. By the end of 2020, the Novo Ventures Investment Portfolio included 68 companies, up from 65 at the end of 2019 and was valued at DKK 14 billion.
In the years to come, we will continue to grow the amount we invest in both private and public companies.